by Jordana Choucair | Jan 20, 2023 | Life Sciences
The Food and Drug Administration (FDA) rejected Eli Lilly & Co.’s attempt for accelerated approval for its Alzheimer’s therapy donanemab because not enough patients in the trial had received the drug for a full year. The company said the FDA did not...
by Jordana Choucair | Jan 19, 2023 | Life Sciences
A new report from the Government Accountability Office found that the Department of Health and Human Services’ (HHS) process for monitoring high-risk research on viruses and other agents that can cause pandemics does not meet the standards for effective...
by Jordana Choucair | Jan 19, 2023 | Life Sciences
The National Institute of Allergy and Infectious Diseases reported that a Phase 3 clinical trial of Janssen’s HIV vaccine was stopped because the vaccine was ineffective. The trial began in 2019 and included 3,900 gay men and transgender people at over 50 sites in...
by Jordana Choucair | Jan 18, 2023 | Life Sciences
Moderna Inc. said its experimental RSV vaccine was 83.7 percent effective in a large clinical trial at lowering the risk of a viral respiratory disease in older adults. The company said it will apply for U.S. approval in the coming months, potentially allowing the...
by Jordana Choucair | Jan 17, 2023 | Life Sciences
Pfizer Inc. said it will sell its drugs to 45 low-income countries at a not-for-profit price, including off-patent medicines like chemotherapies and oral cancer treatments. The pharmaceutical manufacturer will now offer 500 products as part of a program to increase...
by Jordana Choucair | Jan 17, 2023 | Life Sciences
The Centers for Disease Control and Prevention (CDC) said that it is “very unlikely” the Pfizer omicron booster carries a risk of stroke for seniors. According to a CDC spokesperson, the Vaccine Safety Datalink detected that 130 of the 550,000 seniors who received the...
Recent Comments